Page last updated: 2024-12-05

3,4-dimethylphenol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

3,4-dimethylphenol: RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

3,4-xylenol : A member of the class of phenols that is phenol substituted by methyl groups at positions 3 and 4. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID7249
CHEMBL ID192008
CHEBI ID39839
SCHEMBL ID125704
MeSH IDM0175606

Synonyms (77)

Synonym
nsc1549
4-hydroxy-1,2-dimethylbenzene
nsc-1549
4,5-dimethylphenol
wln: qr c1 d1
1-hydroxy-3,4-dimethylbenzene
3,4-dmp
3,4-xylenol
1,4-xylenol
95-65-8
3,4-dimethylphenol
phenol, 3,4-dimethyl-
inchi=1/c8h10o/c1-6-3-4-8(9)5-7(6)2/h3-5,9h,1-2h
2MP ,
NCGC00091845-01
3,4-dimethyl phenol
ccris 723
hsdb 5294
nsc 1549
brn 1099267
ai3-01552
einecs 202-439-5
fema no. 3596
3,4-xylenol, >=98%, fg
3,4-dimethylphenol, 98%
CHEBI:39839 ,
1,2-dimethyl-4-hydroxybenzene
1,3,4-xylenol
DB04052
AC-10834
D0777
3,4-dimethyl-phenol
CHEMBL192008
3,4--xylenol
AKOS000119349
NCGC00091845-03
NCGC00091845-02
NCGC00259073-01
tox21_300185
cas-95-65-8
dtxsid4024062 ,
tox21_201523
dtxcid004062
NCGC00253983-01
4-hydroxy-o-xylene
4l479f5ju6 ,
ec 202-439-5
unii-4l479f5ju6
4-06-00-03099 (beilstein handbook reference)
FT-0614380
SCHEMBL125704
xylenol 3,4-dimethylphenol
3,4-xylenol [fhfi]
xylenol 3,4-dimethylphenol [mi]
metacresol impurity l [ep impurity]
3,4-dimethylphenol [hsdb]
Q-200346
STR06236
F0001-2276
mfcd00002304
3,4-dimethylphenol, pestanal(r), analytical standard
3,4-dimethylphenol 100 microg/ml in methanol
1,2,4-xylenol
3, 4-xylenol
1-hydroxy-3, 4-dimethylbenzene
fema 3596
asym-o-xylenol
3,4-xylenol, 8ci
3,4-dimethylphenol (1)
bdbm238309
Q4634081
STL570694
AM10802
E78877
EN300-20195
PD006522
Z104477218
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
phenolsOrganic aromatic compounds having one or more hydroxy groups attached to a benzene or other arene ring.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (10)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
GLI family zinc finger 3Homo sapiens (human)Potency0.75160.000714.592883.7951AID1259392
AR proteinHomo sapiens (human)Potency50.11870.000221.22318,912.5098AID588516
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency73.31130.003041.611522,387.1992AID1159552; AID1159553; AID1159555
farnesoid X nuclear receptorHomo sapiens (human)Potency53.68640.375827.485161.6524AID743217
estrogen nuclear receptor alphaHomo sapiens (human)Potency29.16350.000229.305416,493.5996AID743069; AID743078
peroxisome proliferator-activated receptor deltaHomo sapiens (human)Potency60.23710.001024.504861.6448AID743212
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_aHomo sapiens (human)Potency0.001419.739145.978464.9432AID1159509
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency53.08040.000627.21521,122.0200AID651741
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Carbonic anhydrase 1Homo sapiens (human)IC50 (µMol)512.58750.00582.14107.9000AID1803186; AID1803187
Carbonic anhydrase 2Homo sapiens (human)IC50 (µMol)512.58750.00021.10608.3000AID1803186; AID1803187
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (12)

Processvia Protein(s)Taxonomy
one-carbon metabolic processCarbonic anhydrase 1Homo sapiens (human)
morphogenesis of an epitheliumCarbonic anhydrase 2Homo sapiens (human)
positive regulation of synaptic transmission, GABAergicCarbonic anhydrase 2Homo sapiens (human)
positive regulation of cellular pH reductionCarbonic anhydrase 2Homo sapiens (human)
angiotensin-activated signaling pathwayCarbonic anhydrase 2Homo sapiens (human)
regulation of monoatomic anion transportCarbonic anhydrase 2Homo sapiens (human)
secretionCarbonic anhydrase 2Homo sapiens (human)
regulation of intracellular pHCarbonic anhydrase 2Homo sapiens (human)
neuron cellular homeostasisCarbonic anhydrase 2Homo sapiens (human)
positive regulation of dipeptide transmembrane transportCarbonic anhydrase 2Homo sapiens (human)
regulation of chloride transportCarbonic anhydrase 2Homo sapiens (human)
carbon dioxide transportCarbonic anhydrase 2Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (6)

Processvia Protein(s)Taxonomy
arylesterase activityCarbonic anhydrase 1Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 1Homo sapiens (human)
protein bindingCarbonic anhydrase 1Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 1Homo sapiens (human)
hydro-lyase activityCarbonic anhydrase 1Homo sapiens (human)
cyanamide hydratase activityCarbonic anhydrase 1Homo sapiens (human)
arylesterase activityCarbonic anhydrase 2Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 2Homo sapiens (human)
protein bindingCarbonic anhydrase 2Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 2Homo sapiens (human)
cyanamide hydratase activityCarbonic anhydrase 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (6)

Processvia Protein(s)Taxonomy
cytosolCarbonic anhydrase 1Homo sapiens (human)
extracellular exosomeCarbonic anhydrase 1Homo sapiens (human)
cytoplasmCarbonic anhydrase 2Homo sapiens (human)
cytosolCarbonic anhydrase 2Homo sapiens (human)
plasma membraneCarbonic anhydrase 2Homo sapiens (human)
myelin sheathCarbonic anhydrase 2Homo sapiens (human)
apical part of cellCarbonic anhydrase 2Homo sapiens (human)
extracellular exosomeCarbonic anhydrase 2Homo sapiens (human)
cytoplasmCarbonic anhydrase 2Homo sapiens (human)
plasma membraneCarbonic anhydrase 2Homo sapiens (human)
apical part of cellCarbonic anhydrase 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (7)

Assay IDTitleYearJournalArticle
AID310931Partition coefficient, log P of the compound2007Journal of medicinal chemistry, Feb-22, Volume: 50, Issue:4
In silico and in vitro filters for the fast estimation of skin permeation and distribution of new chemical entities.
AID310932Permeability across human Skin2007Journal of medicinal chemistry, Feb-22, Volume: 50, Issue:4
In silico and in vitro filters for the fast estimation of skin permeation and distribution of new chemical entities.
AID311367Permeability coefficient in human skin2007Bioorganic & medicinal chemistry, Nov-15, Volume: 15, Issue:22
Transdermal penetration behaviour of drugs: CART-clustering, QSPR and selection of model compounds.
AID237685Lipophilicity determined as logarithm of the partition coefficient in the alkane/water system2005Journal of medicinal chemistry, May-05, Volume: 48, Issue:9
Calculating virtual log P in the alkane/water system (log P(N)(alk)) and its derived parameters deltalog P(N)(oct-alk) and log D(pH)(alk).
AID310933Permeability across PAMPA membrane after 7 hrs2007Journal of medicinal chemistry, Feb-22, Volume: 50, Issue:4
In silico and in vitro filters for the fast estimation of skin permeation and distribution of new chemical entities.
AID1803187CA Activity Assay from Article 10.3109/14756366.2012.693919: \\Synthesis and characterization of phenolic Mannich bases and effects of these compounds on human carbonic anhydrase isozymes I and II.\\2013Journal of enzyme inhibition and medicinal chemistry, Apr, Volume: 28, Issue:2
Synthesis and characterization of phenolic Mannich bases and effects of these compounds on human carbonic anhydrase isozymes I and II.
AID1803186Esterase Activity Assay from Article 10.3109/14756366.2012.693919: \\Synthesis and characterization of phenolic Mannich bases and effects of these compounds on human carbonic anhydrase isozymes I and II.\\2013Journal of enzyme inhibition and medicinal chemistry, Apr, Volume: 28, Issue:2
Synthesis and characterization of phenolic Mannich bases and effects of these compounds on human carbonic anhydrase isozymes I and II.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (16)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's7 (43.75)18.2507
2000's5 (31.25)29.6817
2010's4 (25.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 40.48

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index40.48 (24.57)
Research Supply Index2.83 (2.92)
Research Growth Index4.40 (4.65)
Search Engine Demand Index55.09 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (40.48)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other16 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]